Ex vivo chemosensitivity to @entity1138 in XXXX and its relationship with @entity1262 and apoptotic factors.

@entity1 @entity8214 @entity1262 @entity522 @entity5 @entity1138 @entity1139 @entity150 @entity855
BACKGROUND: Intravesical treatment with @entity1138 ( @entity1139 ) leads to a complete response rate of around 40% in superficial @entity150 ( @entity8214 ). In order to determine in advance which @entity1 will fail to respond, we describe a study assessing the feasibility of applying the @entity855 assay to test the chemosensitivity of samples from @entity1 with this disease. MATERIALS AND METHODS: TURBT or biopsy samples were received from 27 @entity1 , 23 of which were suitable for the @entity855 assay (16 primary @entity5 and 7 recurrences). RESULTS: The success rate of the assay was 91%. There was a marked variation in the effect of @entity1139 between @entity1 with a > 50-fold range in LC50 values (drug concentration required to kill 50% of cells) from 2.99- > 150 microM with a median value of 22.4 microM. We were unable to determine any overall correlation between chemosensitivity and @entity5 stage or grade or the treatment status of the @entity1 in this small data set. @entity1262 status and @entity522 levels were assessed on these samples using immunohistochemistry but there did not appear to be any relationship between either of these parameters and @entity1139 resistance. Apoptotic counts and mitotic counts were also measured but, whilst these appeared to correlate with grade (p < 0.01), there was no overall significant relationship established with @entity1139 chemosensitivity. CONCLUSION: This study suggests that it is possible to use the @entity855 assay for chemosensitivity testing in TCCs. Despite a lack of overall correlation between ex vivo @entity1139 resistance and the conventional prognostic factors tested, further studies are warranted in a larger data set to test the ability of this technique to predict clinical outcome in this disease.
